Small molecule allosteric modulators of phosphodiesterase 4.


Phosphodiesterase 4 (PDE4) inhibitors have shown benefit in human clinical trials but dosing is limited by tolerability, particularly because of emesis. Novel cocrystal structures of PDE4 catalytic units with their regulatory domains together with bound inhibitors have revealed three different PDE4 conformers that can be exploited in the design of novel… (More)
DOI: 10.1007/978-3-642-17969-3_7

7 Figures and Tables


  • Presentations referencing similar topics